Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis

Sabine Cepok, PhD; Herbert Schreiber, MD; Steve Hoffmann, MD; Dun Zhou, MD; Oliver Neuhaus, MD; Gloria von Geldern, MD; Sonja Hochgesand; Stefan Nessler, MD; Veith Rothhammer, MD; Michael Lang, MD; Hans-Peter Hartung, MD; Bernhard Hemmer, MD

Background: Interferon beta has been approved for the treatment of multiple sclerosis (MS). It is believed that immunomodulatory rather than antiviral activity of interferon beta is responsible for disease amelioration. The impact of interferon beta on the chemotraction of immune cells has not been fully addressed.

Objective: To address the influence of interferon beta on the expression of chemokines and their receptors in a standardized setting.

Design: The expression of 14 chemokines and 14 chemokine receptor genes was determined by quantitative real-time polymerase chain reaction from fresh blood samples.

Setting: Outpatient units in Germany.

Patients: Untreated and interferon beta–treated patients with MS who tested positive and negative for neutralizing antibodies (NABs) were recruited from August 24, 2006, through December 15, 2006, for the initial study and from March 12, 2007, through April 2, 2007, for the validation study.

Main Outcome Measures: Gene expression and serum chemokine protein levels.

Results: CCL1, CCL2, CCL7, CXCL10, CXCL11, and CCR1 gene expression was strongly upregulated in interferon beta–treated, NAB-negative MS patients. In contrast, gene expression in interferon beta–treated, NAB-positive MS patients did not differ from untreated control donor individuals. Antibody titers inversely correlated with chemokine and chemokine receptor gene expression. Accordingly, serum chemokine protein levels of interferon beta–treated, NAB-negative MS patients were significantly higher than in untreated or interferon beta–treated, NAB-positive MS patients.

Conclusions: We demonstrate that interferon beta strongly upregulates a set of chemokines and CCR1 in peripheral immune cells. The peripheral upregulation of these chemokines may reduce the chemotraction of immune cells to the central nervous system and thus add to the therapeutic effects of interferon beta.

Arch Neurol. 2009;66(10):1216-1223
Because chemokines control cell migration to sites of inflammation, it has been hypothesized that chemokines and their receptors are essential in the recruitment of pathogenic immune cells into the CNS. Although CC chemokines attract mononuclear cells to sites of chronic inflammation, at least some CXC chemokines attract polymorphonuclear cells to sites of acute inflammation.8 Therefore, many studies9-13 in human and animal models have investigated the role of chemokines and their receptors in brain, serum, and cerebrospinal fluid (CSF). In CNS tissue, the chemokines CCL2 (monocyte chemoattractant protein 1 [MCP1]), CCL4 (macrophage inflammatory protein 1β [MIP1β]), CCL5 (regulated on activation of normal T cells expressed and secreted [RANTES]), and CXCL10 (interferon-inducible protein of 10 kDa [IP-10]) were detected in the active demyelination of MS lesions. The related receptors CCR1, CCR2, CCR5, and CXCR3 are mainly expressed on T cells and monocytes and are also found in elevated levels in patients with MS lesions,10,12 which suggests that these cells are specifically attracted to sites of inflammation. More recently, it was shown that CXCL12 and CXCL13 levels were elevated in patients with active MS lesions, which suggests a role of B-cell guidance to the inflamed tissue.14,15 In CSF, CXCL10 was most consistently found to be upregulated and CCL2 was downregulated.16-19 The expression of CXCL10 was reported to be higher in relapsing-remitting MS (RRMS) than in primary progressive MS.18 Since expression of this chemokine was higher in active than in stable MS,19 it may be involved in acute CNS inflammation. Although most T cells in the CSF express the complementary receptor CXCR3 even in noninflammatory conditions, the number of CXCR3+ CD4+ T cells in CSF seems to correlate with disease activity in MS.13,20,21 On the basis of their expression in the inflammatory lesion and their role in immune cell migration, chemokines and their receptors have become attractive therapeutic targets in MS.8,22,23

Interferon beta is the most widely used immunomodulatory drug in the treatment of MS. Interferon beta, a cytokine produced by cells of the innate immune system, is essential to the control of viral infections. In the CNS, microglia and astrocytes produce interferon beta. Although interferon beta reduces relapse rates and activity as seen on magnetic resonance imaging (MRI) and seems to slow progression, its mode of action in MS is still only incompletely understood. Although interferon beta seems to have an effect on immune cell migration, the differential effect on the various chemokines and their receptors has not been fully investigated. We studied RNA transcript expression of 14 chemokines and 14 chemokine receptors in the blood of untreated and interferon beta–treated MS patients. The interferon beta–induced upregulation of gene transcripts was validated in patients who developed neutralizing antibodies against interferon beta.

### METHODS

#### PATIENTS

Seventeen RRMS patients given interferon beta-1a (Avonex; Biogen Idec, Research Triangle Park, North Carolina) intramuscularly once weekly, 9 age-matched untreated RRMS patients, and 8 age-matched healthy control donor individuals were enrolled in the initial study from August 24, 2006, through December 15, 2006. These patients were from the outpatient units of the MS Practice Study Group in Ulm, Germany. Patient characteristics are given in Table 1. For the validation study, an additional group of interferon beta–treated (interferon beta-1a; Avonex) RRMS patients was recruited from March 12, 2007, through April 2, 2007. This second cohort of patients comprised 4 MS patients who developed neutralizing antibodies (NABs) during the treatment compared with 7 MS patients who did not. The study was approved by the ethics committee of the University of Dusseldorf and the Technical University of München.

#### SAMPLE COLLECTION

Fresh blood samples were collected 12 hours after administration of interferon beta. To protect RNA, 5 mL of blood was collected directly in specialized RNA-protecting tubes (PAXgene, PreAnalytix; Qiagen GmbH, Hilden, Germany). Serum samples were collected in parallel. After centrifugation at 1900g for 10 minutes, the serum was aliquoted and stored at –20°C.

#### RNA PREPARATION

High-throughput RNA preparation was performed (PAXgene 96 Blood RNA Kit; Qiagen GmbH). The quality of the RNA was analyzed with a bioanalyzer (Biacore; GE Healthcare, Chalfont St Giles, England). The purity and concentration were determined with photometer (Nanodrop ND1000; PEQLAB Biotechnologie GmbH, Erlanger, Germany) analysis. RNA was immediately reverse transcribed to complementary DNA (cDNA) by a high-capacity cDNA reverse transcription kit (Applied Biosystems Inc, Foster City, California).

#### QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION

The quantitative gene expression analysis was performed using low-density macroarrays from Applied Biosystems Inc. The arrays contained primer pairs and probes (TaqMan gene expression assays; Applied Biosystems Inc) for 14 different chemo-

### Table 1. Characteristics of the Study Participants

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MS Patients</th>
<th>Healthy Control Donor Individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, M/F</td>
<td>6/2</td>
<td>4/1</td>
</tr>
<tr>
<td>Age, mean (range), y</td>
<td>42.9 (33-50)</td>
<td>38.6 (21-55)</td>
</tr>
<tr>
<td>Course, RR/SP/PP</td>
<td>8/0/0</td>
<td>17/0/0</td>
</tr>
<tr>
<td>EDSS score, mean (range)</td>
<td>1.3 (0-3.5)</td>
<td>2.0 (0-3.0)</td>
</tr>
<tr>
<td>Disease duration, mean (range), y</td>
<td>4.6 (2-12)</td>
<td>5.1 (2-11)</td>
</tr>
</tbody>
</table>

Abbreviations: EDSS, Extended Disability Status Scale; MS, multiple sclerosis; NA, not applicable; PP, primary progressive; RR, relapsing-remitting; SP, secondary progressive.
zyme-linked immunosorbent assay (cELISA), as previously de-

Antibodies to interferon beta were determined by a capture en-

CCR9-Hs00258535, CCR10-Hs00706455, CXCR3-

CCR6-Hs00171121, CCR7-Hs00171054, CCR8-Hs00174764,

Hs00266213, CCR4-Hs99999919, CCR5-Hs00152917,

Hs00757930, CCR1-Hs00174298, CCR2-Hs00356601, CCR3-

Hs00266213, CCR4-Hs99999919, CCR5-Hs00152917,

CCR6-Hs00174764, CCR7-Hs00171054, CCR8-Hs00174764,

CCL21-Hs00171076, CXCL3-Hs00171061, CXCL5-

CCL21-Hs00171065, CXCL10-Hs00174298, CXCR2-Hs00356601, CCR3-

CCL17-Hs00171054, CCR6-Hs00174298, CCR2-Hs00356601, CCR3-

CXCL11-Hs00171061, CXCL5-Hs00171085, CXCL9-Hs00171074,

CXCL12-Hs00171022, CXCL13-Hs00757930, CCR1-Hs00174298, CXCR2-Hs00356601, CCR3-

CXCL13-Hs00757930, CCR1-Hs00174298, CXCR2-Hs00356601, CCR3-

CXCL11-Hs00171061, CXCL5-Hs00171085, CXCL9-Hs00171074,

CXCL12-Hs00171065, CXCL10-Hs00174298, CXCL11-Hs00171138, CXCL12-Hs00171022, CXCL13-

CXCL11-Hs00171138, CXCL12-Hs00171022, CXCL13-

CXCL11-Hs00171041, CXCR4-Hs00237052, CX3CR1-Hs00365842, and

XCR1-Hs00245540.

NAB ASSAY

Antibodies to interferon beta were determined by a capture en-

zyme-linked immunosorbent assay (cELISA), as previously de-

scribed.24,25 Antibody titers were considered positive when they

exceeded 5 SDs of the median of untreated patients and con-

fants. The binding capacity of each serum sample was calculated

tive samples. The biological activity of the antibodies was determined by the in vitro induction of MxA after interferon

beta injection.4 The RNA expression level of MxA was deter-

mined 12 hours after interferon beta injection in each blood sample by quantitative real-time polymerase chain reaction (PCR). The MxA was normalized to GAPDH expression, and the relative

epression compared with standard samples was calculated. The values are expressed as percentage of MxA induction relative to the MxA induction of newly treated MS patients. A value of 100%

corresponds to a normal MxA induction after interferon beta therapy, and 0% corresponds to MxA levels observed in

untreated patients and healthy control donor individuals. Patients were considered to have high titers of NABs when antibodies were detected by cELISA and the MxA response was reduced to the

level of untreated MS patients.

ELISA FOR QUANTIFICATION

OF CHEMOKINES

CXCL11 and CCL2 were measured in serum by Duoset ELISA (R&D Systems, Minneapolis, Minnesota) according to the in-

structions from the manufacturer. The chemokine concentra-
tion was determined in 100 µL of the serum of each patient. All samples were processed in parallel and measured in the same

assays. The concentration of CXCL11 and CCL2 was deter-

mined in 16 untreated MS patients, 19 interferon beta–treated

MS patients without NAB, and 7 interferon beta–treated MS

patients with NAB. The concentration of CCL2 was deter-

mined in 10 untreated MS patients, 16 interferon beta–treated, NAB-negative MS patients, and 8 interferon beta–treated, NAB-

positive MS patients.

FLOW CYTOMETRY–BASED CELL SORTING

Peripheral blood mononuclear cells (PBMCs) isolated from 2

mL of peripheral blood were resuspended in 100 µL of phos-

phate-buffered saline and 5% fetal calf serum and stained with

10 µL of anti-CD19 allophycocyanin (B cells), anti-CD56 phyco-
yrthrin (natural killer cells), and anti-CD3 fluorescein isothio-
cyanate (T cells) and incubated for 10 minutes at 4°C. After 1

washing with phosphate-buffered saline and 5% fetal calf se-

rum, sorting of 4 different immune subsets was performed on a
cell sorter (FACS Aria; Becton, Dickinson and Company, Franklin Lakes, New Jersey). Monocytes were sorted accord-
ing to forward and sideward scatter properties. All antibodies were purchased from Becton, Dickinson and Company. From each cell subset, 5000 cells were sorted. The RNA was imme-

ediately isolated and reverse transcribed to cDNA.

NONPARAMETRIC ANALYSIS

The Wilcoxon rank sum test was used to compare the expres-
sion between untreated and interferon beta–treated patients. The parametric t test was used to compare the chemokine expression between groups. To adjust for multiple testing, the false discov-
ery rate was calculated for each comparison. An expression was

considered statistically significant when the P value was lower or

equal to the false discovery rate for the analyzed gene. The Spear-
mann rank correlation was applied to determine the relation be-
tween anti–interferon beta antibodies and the gene expression and

between the MxA induction and the gene expression.

Table 2. Quantitative Expression Analysis of Chemokines and Chemokine Receptors in Nontreated Compared With Interferon Beta-1a–Treated Multiple Sclerosis Patients

<table>
<thead>
<tr>
<th>Gene Chemokine</th>
<th>CCL1</th>
<th>CCL2</th>
<th>CCL5</th>
<th>CCL7</th>
<th>CCL11</th>
<th>CCL17</th>
<th>CCL21</th>
<th>CCLX3</th>
<th>CCLX5</th>
<th>CCLX9</th>
<th>CXCL10</th>
<th>CXCL11</th>
<th>CXCL12</th>
<th>CXCL13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nontreated Mean (Range)</td>
<td>1.3 (0.3-3.8)</td>
<td>0.9 (0.6-1.3)</td>
<td>1.3 (0.8-1.7)</td>
<td>1.0 (0.4-1.9)</td>
<td>1.1 (0.7-2.8)</td>
<td>0.7 (0.4-1.6)</td>
<td>0.6 (0.3-1.3)</td>
<td>1.6 (0.2-2.6)</td>
<td>1.0 (0.5-2.7)</td>
<td>1.9 (0.2-4.5)</td>
<td>1.8 (0.2-4.0)</td>
<td>2.2 (0.9-9.8)</td>
<td>4.5 (0.2-16.2)</td>
<td>1.4 (0.4-2.2)</td>
</tr>
<tr>
<td>Interferon Beta-1a–Treated Mean (Range)</td>
<td>27.8 (1.2-112.9)</td>
<td>110.9 (5.0-454.1)</td>
<td>12.0 (8.1-18.1)</td>
<td>85.3 (4.0-462.0)</td>
<td>13.6 (6.2-26.8)</td>
<td>8.3 (3.1-16.3)</td>
<td>6.2 (2.1-13.3)</td>
<td>17.0 (2.3-34.2)</td>
<td>11.1 (7.1-19.9)</td>
<td>4.7 (1.0-12.4)</td>
<td>155.1 (1.0-965.7)</td>
<td>135.5 (3.9-667.9)</td>
<td>14.4 (5.0-50.1)</td>
<td>3.9 (0.6-10.8)</td>
</tr>
<tr>
<td>P Value</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td>.01</td>
<td>&lt;.001</td>
<td>.001</td>
<td>&lt;.001</td>
<td>.98</td>
<td>.84</td>
<td>&lt;.001</td>
<td>.007</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td>.02</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

The quantitative gene expression was assessed by the Applied Biosystems Inc 7900 real-time thermocycler (Applied Biosystems Inc). For analysis, the expression level of each gene was normalized in reference to the housekeeping gene GAPDH (ΔCt). The normalized values of untreated and interferon beta–treated MS patients were calibrated against the normalized value of healthy control donor individuals. Therefore, all gene transcriptions are expressed as n-fold changes relative to healthy control donor individuals (ΔΔCt). The following predesigned TaqMan gene expression assays were selected (all from Applied Biosystems Inc): CCL1-Hs00171072, CCL2-Hs00234140, CCL5-Hs00174575, CCL7-Hs00171147, CCL11-Hs00237013, CCL17-Hs00171074, CCL21-Hs00171076, CXCL3-Hs00171061, CXCL5-Hs00171085, CXCL9-Hs00171065, CXCL10-Hs00171042, CXCL11-Hs00171138, CXCL12-Hs00171022, CXCL13-Hs00757930, CCR1-Hs00174298, CCR2-Hs00356601, CCR3-Hs00266213, CCR4-Hs99999919, CCR5-Hs00152917, CCR6-Hs00171121, CCR7-Hs00171054, CCR8-Hs00174764, CCR9-Hs00258535, CCR10-Hs00706455, CX3CR1-Hs00171041, CXCR4-Hs00237052, CX3CR1-Hs00365842, and XCR1-Hs00245540.

©2009 American Medical Association. All rights reserved.

Downloaded From: by a Non-Human Traffic (NHT) User on 11/13/2018
The aim of the study was to determine the influence of interferon beta on the expression of chemokine and chemokine receptor genes in vivo. Using a low-density macroarray for quantitative real-time PCR, we determined the expression of 14 chemokines and 14 chemokine receptors in blood samples of 8 untreated MS patients, 17 interferon beta–treated MS patients, and 9 healthy control donor individuals. Patient characteristics are given in Table 1. To compare the untreated and interferon beta–treated MS patients, the expression of each gene was normalized to the endogenous control gene GAPDH, and the n-fold expression difference compared with the expression gene in healthy control donor individuals was determined in each patient (Table 2). Overall, no significant expression difference was observed between untreated MS patients and healthy control donor individuals. The expression of most genes was also not influenced by the administration of interferon beta. By contrast, 5 chemokines, CCL1, CCL2, CCL7, CXCL10, and CXCL11, and 1 chemokine receptor, CCR1, were strongly upregulated in the blood of interferon beta–treated MS patients compared with untreated MS patients. The chemokines CXCL9 and CXCL12 were moderately upregulated (Figure 1). None of the chemokine or chemokine receptor genes was significantly downregulated in interferon beta–treated MS patients compared with untreated MS patients.

INFLUENCE OF NEUTRALIZING ANTIBODIES ON CHEMOKINE EXPRESSION

It is well known that up to 30% of interferon beta–treated MS patients develop NABs to interferon beta.26,27 These antibodies interfere with the therapeutic activity of interferon beta. To validate the impact of interferon beta on chemokine and chemokine receptor gene induction, we performed gene expression analysis in a second independent group of MS patients treated with interferon beta. The group included patients who had developed NABs and patients who were NAB negative. Four patients had high titers of interferon beta–specific antibodies and completely lost their interferon beta–induced MxA response. Seven patients were NAB negative and showed the expected strong upregulation of MxA gene transcripts in the peripheral blood (Figure 2A). When we determined chemokine transcript levels in those patients, we found that NAB-positive patients had expression levels of CCL1, CCL2, CCL7, CXCL9, CXCL10, CXCL11, CXCL12, and CCR1 comparable to untreated MS patients and controls (Figure 2B). By contrast, NAB-negative patients showed upregulation of all 8 genes comparable to the first patient group (Figure 1 and Figure 2B). In 1 patient, who developed NABs during interferon beta treatment, we had the opportunity to analyze the expression of chemokine and chemokine receptor genes before and after the patient had developed NABs. As expected, the expression of CCL1, CCL2, CCL7, CXCL9, CXCL10, CXCL11, and CXCL12 decreased once NABs had developed (Figure 2C and D). By contrast, interferon beta–dependent upregulation of chemokine genes did not change over time in patients who remained NAB negative (data not shown). Next, we analyzed the relation between NAB titer and the regulation of chemokine and chemokine receptor gene expression in interferon beta–treated patients. Induction of chemokine and chemokine receptor gene transcripts correlated strongly with transcripts of the interferon beta response gene MxA (R=0.82). An inverse correlation was observed between chemokine and chemokine receptor gene expression in peripheral immune cells and the level of interferon beta–specific antibody (R=−0.67).

Figure 1. Expression of CCL1, CCL2, CCL7, CXCL9, CXCL10, CXCL11, and CCR1 in untreated and interferon beta–treated patients with multiple sclerosis (MS). Shown are all chemokines (A) and chemokine receptor gene transcripts (B), which were significantly upregulated in patients treated with interferon beta (see also Table 2). The expression level of each gene was normalized by the housekeeping gene GAPDH (6×CT). The normalized values of untreated and interferon beta–treated MS patients were calibrated with normalized values of healthy control donor individuals. Therefore, all gene transcriptions are expressed as n-fold changes relative to healthy control individuals (6×CT) and transformed to log_{10} for presentation. Each dot represents 1 patient. nt indicates untreated MS patients; IFN, interferon beta–ta-treated MS patients.

Figure 2. CHEMOKINE AND CHEMOKINE RECEPTOR EXPRESSION IN VIVO DURING INTERFERON BETA THERAPY

©2009 American Medical Association. All rights reserved.
Next, we investigated whether the increased expression of chemokine RNA in the blood results in higher chemokine protein serum levels. As shown for the CC chemokine CCL2, interferon beta–treated patients (mean, 340 pg/mL) had significantly higher chemokine levels compared with untreated MS patients (mean, 103 pg/mL) (Figure 3A). We also determined the serum concentration of CXCL11 and found a significant upregulation in interferon beta–treated (mean, 317 pg/mL) compared with untreated MS patients (mean, 57 pg/mL) for a CXC chemokine (Figure 3B). We also determined the serum level in NAB-positive patients for both chemokines. By contrast, chemokine levels in the serum of patients with NABs did not differ from the levels in untreated patients (Figure 3A and B). Similar to the RNA transcripts, we found a strong positive correlation between MxA gene upregulation and the protein concentration in serum as shown for CXCL11 (Figure 3C).

To identify the cellular source of chemokine upregulation in response to interferon beta, we analyzed RNA expression in different immune subsets isolated from the PBMCs of 2 interferon beta–treated patients compared with 1 untreated MS patient (Figure 4). As exemplified for CXCL11, we demonstrated that interferon beta mainly upregulates chemokine expression by monocytes, whereas little to no changes were observed in other immune cell subsets.

**COMMENT**

Interferon beta is the most widely used immunomodulatory drug in the treatment of MS that exerts a significant impact on relapse rate and inflammatory MRI activity. However, the detailed mechanism of the way...
that interferon beta acts in MS is still unclear. One possible mode of interferon beta action may be an effect on the expression of chemokines and their receptors and thereby modulates the migration of immune cells to brain parenchyma. Several studies have investigated the influence of interferon beta in vitro and in vivo with a focus on selected chemokines or chemokine receptors. However, conflicting results have been reported.

We aimed to analyze the impact of interferon beta on the expression of a set of 14 chemokines and 14 chemokine receptors by quantitative real-time PCR in a standardized setting. Blood was taken 12 hours after the last interferon beta injection, and the messenger RNA expression level was determined directly ex vivo in fresh whole blood samples. We demonstrate that interferon beta selectively upregulates CCL1, CCL2, CCL7, CXCL10, and CXCL11. The chemokines CXCL9 and CXCL12 were moderately upregulated. The impact on chemokine receptor expression was less pronounced, with CCR1 being the only significantly upregulated gene. We confirmed our findings in a second group of interferon beta–treated patients, including patients who developed NABs during their treatment with interferon beta. Although the same chemokine induction was seen in interferon beta–treated, NAB-negative patients, the effect was completely abolished in treated NAB-positive patients. Antibody titers to interferon beta inversely correlated with chemokine induction, a result that further supports the specific effect of interferon beta on those chemokines.

Interestingly, upregulation of chemokine genes, as exemplified for CXCL11, was strongest in monocytes compared with all other peripheral immune subsets, although all were exposed to interferon beta.

The results of our study were somewhat surprising. The chemokines that we found to be upregulated in response to interferon beta specifically bind to CXCR3 and CCR5, which are expressed on activated memory T cells; CCR1, CCR2, CCR3, and CCR5, which are expressed on mono-

![Figure 4. RNA transcript analysis of CXCL11 in different immune cell subsets.](image)

Figure 4. RNA transcript analysis of CXCL11 in different immune cell subsets. B cells, T cells, natural killer (NK) cells, and monocytes were sorted from peripheral blood mononuclear cells and the RNA expression level as determined by quantitative reverse transcriptase–polymerase chain reaction. The RNA expression level of 2 interferon beta–treated multiple sclerosis (MS) patients is expressed as n-fold changes relative to the untreated MS patient.

Figure 3. Elevated chemokine protein levels in serum and the cellular source of chemokine upregulation induced by interferon beta. Serum concentrations of CCL2 (A) and CXCL11 (B) were determined in untreated, interferon beta–treated, neutralizing antibody (NAB)–negative patients with multiple sclerosis (MS) and interferon beta–treated, NAB-positive patients with MS. The Wilcoxon rank sum test was used for statistical analysis. C. The serum concentration of CXCL11 was correlated with the MxA gene induction of each patient determined in section B. According to the gene expression, the protein synthesis strongly correlated with MxA induction. The Spearman rank correlation was used for statistical analysis. Each dot represents 1 patient.

... and macrophages; and CXCR4, which is expressed on B cells. All these cells are typically found in MS lesions. It is puzzling that, although its anti-inflammatory activity has been well established in the treatment of MS, interferon beta induces an upregulation of proinflammatory chemokines, which represent the specific ligands of immune cell receptors found in CNS lesions.

There are several conceivable ways systemic upregulation of chemokines may reduce CNS inflammation in MS. Characteristically, the transmigration of leukocytes across the blood-brain barrier into the CNS is regulated by sequential interaction between adhesion molecules on leukocytes and endothelial cells and chemokines that are immobilized on endothelial cells and the chemokine receptors expressed on activated leukocytes. Cells that...
express the corresponding receptor bind the chemokine and undergo rapid cytoskeletal rearrangement followed by migration toward a higher concentration of the chemokines. At higher concentrations, some chemokines can spontaneously form oligomers or heteromers, which strongly enhance leukocyte migration and activation. As observed in our study, chemokines are strongly upregulated in the periphery, which may indeed decrease or even reverse the gradient between the inflammatory lesion and the peripheral immune compartment. This may prevent cell migration to the lesion or even drive cells back from the lesion to the periphery. In detail, all 3 CXCR3 agonists, CXCL9, CXCL10, and CXCL11, may prevent the attraction of CXCR3+ T cells, CCL7 of CCR1+ monocytes, and CCL2 together with CCL7 of CCR2+ monocytes, and CXCL12 of CXCR4+ B cells. Because the CCR8 receptor is expressed on a subset of memory CD4+ T cells that comprise Treg2 effector T cells and also regulatory T cells, the upregulation of CCL1 could lead to enhanced migration of regulatory T cells to the inflammatory site, which may regulate the inflammatory response in the CNS. As an additional concept, the exposure to high chemokine concentrations may desensitize the chemokine receptors in cells of the immune system. The exposure to high concentrations of chemokines often results in the rapid attenuation and desensitization of the receptor by receptor phosphorylation followed by uncoupling of the receptor from heterotrimeric G proteins and internalization of the receptor. Internalization leads to the reduction of surface expression of the receptor, which leaves the cell unresponsive to further stimuli without significant changes in RNA level. Elevated chemokine concentrations in serum, as observed in our study, could thus prolong the unresponsiveness of the cell until the chemokines are consumed.

Both hypotheses are supported by several studies that demonstrated a reduced surface expression of CCR5 and CXCR3 on the PBMCs of interferon beta–treated MS patients. This concept is also supported by the analysis of serum CXCL10 and CCL2 after interferon beta administration. When blood was taken 6 hours after the last interferon injection, levels of both chemokines were elevated but decreased to normal within 24 hours. In a study with sampling 9 to 12 hours after the last injection, plasma levels of CCL3, CCL4, CCL5, and CXCL9 were unaltered, but the CXCL10 level was increased after interferon beta therapy. In line with our results, CCL2 serum concentration significantly increased as shown by others. In vitro studies in which PBMCs exposed to interferon beta were analyzed for early interferon beta responsive genes by cDNA microarray analysis support our findings. The analysis revealed that the RNA expression of CXCR3 ligands CXCL9, CXCL10, and CXCL11 and CCR2 ligands CCL2 and CCL5 was upregulated after a 3-hour exposure to interferon beta in culture. Although we did not observe a downregulation of any chemokine, others have shown reduced serum levels for CXCL8 and reduced CXCL1 RNA expression ex vivo. Neither chemokine was analyzed in our study.

In summary, our in vivo data provide strong evidence that interferon beta has an influence on the expression of particular chemokines and receptors. The induction of chemokine expression in the periphery may affect migration of immune cells to the inflammatory lesions. This may explain the rapid onset of the anti-inflammatory activity of interferon beta in treated patients. Additional studies are warranted to determine whether this effect is central to the therapeutic efficacy of interferon beta.

Accepted for Publication: January 14, 2009.
Correspondence: Bernhard Hemmer, MD, Department of Neurology, Klinikum rechts der Isar, Technische Universität, 81675 München, Germany (hemmer@lrz.tu-muenchen.de).

Author Contributions: Study concept and design: Cepok, Schreiber, Lang, Hartung, and Hemmer. Acquisition of data: Cepok, Schreiber, Zhou, Neuhaus, Hochgesand, Rothsammer, Lang, and Hemmer. Analysis and interpretation of data: Cepok, Hoffmann, von Geldern, Nessler, Hartung, and Hemmer. Drafting of the manuscript: Cepok and Hemmer. Critical revision of the manuscript for important intellectual content: Cepok, Schreiber, Hoffmann, Zhou, Neuhaus, von Geldern, Hochgesand, Nessler, Rothsammer, Lang, Hartung, and Hemmer. Statistical analysis: Hoffmann. Obtained funding: Lang and Hemmer. Administrative, technical, and material support: Schreiber, Zhou, Nessler, Lang, Hartung, and Hemmer. Study supervision: Cepok, Schreiber, and Hemmer.

Financial Disclosure: None reported.

Funding/Support: The research work was funded by the European Union (Neutralizing Antibodies on Interferon Beta in Multiple Sclerosis), Deutsche Forschungsgemeinschaft (He 2386/7-1), and Biogen Idec.

Additional Contributions: We thank all our patients for their continual support and Clarissa Klein and Annette Kuck for excellent technical support.

REFERENCES


